Generics of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir) are on the horizon, with ...

Despite possessing a solid data package on the potential of high-dose Sprinraza in spinal muscular atrophy (SMA), Biogen will ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

A Johnson & Johnson innovate medicine subsidiary, Janssen Vaccines, landed in hot water with the FDA this summer over a 2024 ...

There’s no doubt that growing up on pandemic-era online schooling and TikTok trends has set the Generation Z experience apart ...

While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...

In recent years, Roche has made a habit of oscillating between first and second place on rare disease patient groups’ annual ...

After Madison Norman graduated with an undergraduate degree in business administration from Boston University and then a ...

X4 Pharmaceuticals is again shrinking its workforce, this time by 50% as the company pushes to save costs and finish a phase ...

Eli Lilly has been censured by the U.K. marketing watchdog after a complainant reported being hit by a “bombardment of spam.” ...

SK Biopharmaceutical’s Xcopri (cenobamate) met the bar in a phase 3 trial that could support the company’s ambitions of ...

Bristol Myers Squibb is exiting the first U.S.-China pharmaceutical joint venture. Kalexo Bio and Ollin Biosciences have ...